RT Journal Article
SR Electronic
T1 Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.21.24317726
DO 10.1101/2024.11.21.24317726
A1 Esmaeili, Shadisadat
A1 Owens, Katherine
A1 Wagoner, Jessica
A1 Polyak, Stephen J.
A1 Zhang, Shengyuan
A1 Standing, Joseph F.
A1 Lowe, David M.
A1 Schiffer, Joshua T.
YR 2024
UL http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317726.abstract
AB Molnupiravir is an antiviral medicine that induces lethal copying errors into SARS-CoV-2 RNA. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials. We used mathematical models to simulate these trials and closely recapitulated their virologic outcomes. Model simulations suggest lower antiviral potency against pre-omicron SARS-CoV-2 variants than against omicron. We estimate that in vitro assays underestimate in vivo potency 7-8 fold against omicron variants. Our model suggests that because polymerase chain reaction detects molnupiravir mutated variants, the true reduction in genetically intact viral RNA is underestimated by ∼0.5 log in the two trials, which included participants with omicron. Our results reinforce past work suggesting that in vitro assays are unreliable for estimating in vivo antiviral drug potency and suggest that virologic endpoints for respiratory virus clinical trials should be catered to the drug mechanism of action.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by NIAID R01AI77512-01 (JTS, SP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on GitHub at https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0 Pharmacodynamics data is available on GitHub at https://github.com/sEsmaeili/MolnupiravirModeling https://github.com/gradlab/SC2-kinetics-immune-history https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0 https://github.com/sEsmaeili/MolnupiravirModeling